Malignant Mesothelioma Epidemiology Market | 2021-2026

"The Global Malignant Mesothelioma Epidemiology Market is expected to grow from USD 380.2 million in 2020 to USD 540.8 million by 2026 at a CAGR of over 6.2% during the forecast period".

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Malignant mesothelioma is known as rare cancer that originates from the inner lining of the body’s serous cavities i.e., peritoneum, pleura, pericardium, and vaginal tunic of the testicle. It is caused due to asbestos exposure which can be hidden in the living area or any other object such as curtains, cardboard, toys, and board covers among others.

Market Drivers

The growth of the global malignant mesothelioma epidemiology market is primarily driven by increasing cases of mesothelioma cancer due to asbestos exposure.

• Millions of people around the world are exposed to asbestos. Additionally, the rising geriatric populace across geographies is expected to add to the market growth substantially.
• Furthermore, the growing emphasis on the development of more advanced cancer treatment methods is likely to drive the market growth at a significant rate during the review period.

COVID-19 Impact 

The covid-19 outbreak posed significant challenges to the healthcare system across geographies. It affected the growth of the malignant mesothelioma epidemiology market negatively as patients postponed their treatment due to a rapid surge in COVID-19 cases across geographies. Also, supply chain disruptions due to the imposition of the lockdown affected the installation of equipment in the hospital and thus, affected the market growth.

Segment Analysis

Drug Type Trends

"Pemetrexed segment accounted for the largest market share in 2020"

• The market has been segmented based on drug type into pemetrexed, cisplatin, carboplatin, gemcitabine, vinorelbine, and others.
• The pemetrexed segment accounted for the largest market share in 2020 and is expected to register significant growth over the forecast period.
• The segment growth can be attributed to the increasing use of pemetrexed drugs in combination with other drugs.

Regional Trends

"North America accounted for the largest market share in 2020"

• Geographically, the market in North America accounted for the largest market share in 2020 and is expected to continue its dominance over the forecast period owing to the increasing incidence of cancer disease.
• Additionally, high spending on R&D activities to develop advanced therapies to treat cancer is likely to add to the market growth significantly.
• The market in Asia-Pacific is expected to register a healthy CAGR during the review period on account of the increasing prevalence of cancer and raising awareness about the available cancer treatment methods.

Want to know which region offers the best growth opportunities? Register Here

key Players

The following are the key players in the Malignant Mesothelioma Epidemiology Market (arranged alphabetically)

• AstraZeneca plc (UK),
• Bristol-Myers Squibb Company (The U.S),
• C.H. Boehringer Sohn AG & Ko. KG (Germany),
• Eli Lilly and Company (The U.S),
• F. Hoffmann-La Roche AG (Switzerland),
• Fresenius Kabi AG (Germany) and
• Mylan N.V. (The U.S),
• Merck & Co., Inc. (The U.S),
• Novartis International AG (Switzerland),
• Pfizer Inc. (The U.S),
• Sanofi S.A. (France),
• Sun Pharmaceuticals Industries Ltd (India). 
• Teva Pharmaceutical Industries Ltd (Israel),

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com?

Report Features

This report provides market intelligence most totally. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.